斯钙素2、富含半胱氨酸的酸性分泌蛋白类似蛋白1表达与宫颈癌患者临床特征及预后的关系

Association of STC2 and SPARCL1 expression with clinical features and prognosis in patients with cervical cancer

摘要:

目的 分析宫颈癌组织中斯钙素2（STC2）、富含半胱氨酸的酸性分泌蛋白类似蛋白1（SPARCL1）表达与患者临床特征及预后的关系。方法 选取2021年1月—2023年7月徐州市妇幼保健院收治的90例宫颈癌患者，将其分为观察组（癌组织）和对照组（癌旁正常组织），对比不同组织中STC2、SPARCL1表达情况，分析不同临床特征宫颈癌患者STC2、SPARCL1表达状况及STC2和SPARCL1阳性表达的影响因素，分析不同STC2、SPARCL1表达对宫颈癌患者生存状况的预测价值。结果 观察组STC2阳性率高于对照组，SPARCL1阳性率低于对照组（P <0.05）。浸润深度>1/2纤维肌层、分化程度低和TNM分期为Ⅲ、Ⅳ期患者STC2阳性率高（P <0.05）。分化程度低，TNM分期Ⅲ、Ⅳ期，有淋巴结转移患者的SPARCL1阳性率低（P <0.05）。多因素一般Logistic回归分析，结果显示：浸润深度>1/2纤维肌层［O^R=3.095（95% CI：1.147，8.349）］、分化程度低［O^R=3.020（95% CI：1.122，8.129）］和TNM分期为Ⅲ、Ⅳ期［O^R=4.694（95% CI：1.696，12.992）］均为宫颈癌患者STC2阳性的危险因素（P <0.05）。多因素一般Logistic回归分析，结果显示：有淋巴结转移［O^R=0.211（95% CI：0.084，0.530）］、分化程度低［O^R=0.146（95% CI：0.056，0.375）］和TNM分期为Ⅲ、Ⅳ期［O^R=0.187（95% CI：0.072，0.486）］均为宫颈癌患者SPARCL1阳性的保护因素（P <0.05）。不同STC2、SPARCL1高低表达患者生存曲线比较，差异均无统计学意义（P >0.05）。结论 宫颈癌组织STC2、SPARCL1表达与临床特征及预后密切相关。

Abstract:

Objective To analyze the relationship between the expression of stanniocalcin 2 (STC2) and secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) in cervical cancer tissues and clinical characteristics and prognosis in patients with cervical cancer.Methods A total of 90 patients with cervical cancer admitted to Xuzhou Maternal and Child Health Hospital from January 2021 to July 2023 were selected and divided into the observation group (cancer tissues) and the control group (adjacent normal tissues). The expression of STC2 and SPARCL1 in different tissues was compared. The expression of STC2 and SPARCL1 in cervical cancer patients with different clinical characteristics and the factors affecting the positive expression of STC2 and SPARCL1 were analyzed. The predictive value of STC2 and SPARCL1 expression levels for patient survival was explored.Results The positive rate of STC2 in the observation group was higher than that in the control group (P < 0.05), while the positive rate of SPARCL1 was lower than that in the control group (P < 0.05). Patients withdepth of stromal invasion > 1/2, poor tumor differentiation, or TNM stage III-IV had a higher STC2 positivity rate (P < 0.05). Patients with poor tumor differentiation, TNM stage III-IV, or lymph node metastasis exhibited a higher SPARCL1 positivity rate (P < 0.05). Multivariable logistic regression analysis revealed that depth of stromal invasion > 1/2 [O^R = 3.095 (95% CI: 1.147, 8.349) ], poor tumor differentiation [O^R = 3.020 (95% CI: 1.122, 8.129) ] and TNM stage Ⅲ~Ⅳ [O^R = 4.694 (95% CI: 1.696, 12.992) ] were all risk factors for STC2 positivity in patients with cervical cancer (P < 0.05), and that lymph node metastasis [O^R = 4.048 (95% CI: 1.624, 10.087) ], poor tumor differentiation [O^R = 3.254 (95% CI: 1.259, 8.413) ], and TNM stage Ⅲ~Ⅳ [O^R = 3.474 (95% CI: 1.241, 9.725) ] were all risk factors for SPARCL1 positivity in patients with cervical cancer (P < 0.05). Comparison of survival curves between patients with high and low STC2 or SPARCL1 expression showed no statistically significant differences (P > 0.05).Conclusion STC2 and SPARCL1 expression in cervical cancer tissues is closely associated with clinical features and prognosis.